研究显示,Regeneron的Libtayo药物在高风险皮肤癌患者中复发风险降低68%。 Regeneron's Libtayo drug cuts recurrence risk by 68% in high-risk skin cancer patients, study shows.

Regeneron的C-POST第3阶段试验显示,与安慰剂相比,Adjuvant Libtayo(cemiplimab)在手术后将高风险皮肤癌患者的重发或死亡风险大幅降低68%。 Regeneron's Phase 3 C-POST trial shows that adjuvant Libtayo (cemiplimab) significantly reduces the risk of disease recurrence or death by 68% in high-risk skin cancer patients after surgery, compared to a placebo. 这是首个在高危皮肤状细胞癌患者中显示出这种改善的免疫疗法. This is the first immunotherapy to show such improvement in high-risk cutaneous squamous cell carcinoma patients. 这些结果于2025年1月13日公布, 达到了无疾病生存的首要终点。 The results, announced on January 13, 2025, meet the primary endpoint of disease-free survival.